The Centre for Drug Research and Development



The Centre for Drug Research and Development

September 15, 2011 11:30 ET

The Centre for Drug Research and Development and the National Research Council Canada to Collaborate on New Cancer Therapeutics

VANCOUVER, BRITISH COLUMBIA and MONTREAL, QUEBEC--(Marketwire - Sept. 15, 2011) - The Centre for Drug Research and Development (CDRD) and the National Research Council Canada (NRC) Biotechnology Research Institute today announced that they have entered into a Preferred Collaboration Agreement to develop new antibody-based cancer therapeutics.

Under this Agreement, NRC will leverage its extensive expertise and state-of-the-art facilities to identify monoclonal antibodies that bind cancer cell antigens. Antibodies that require further development will be identified and the CDRD will use its biologics platform to improve the therapeutic activity of those antibodies.

"CDRD is excited to be working with the National Research Council Canada on this important area of research," commented John Babcook, CDRD's Vice President of Biologics. "Recognizing that monoclonal antibodies represent the most successful and fastest growing class of biologics, CDRD recently made the strategic decision to establish a new leading-edge biologics platform at our facility -- a unique resource that will allow us to significantly advance therapeutic candidates identified by NRC."

CDRD and NRC share the goal of transforming discoveries arising from publicly-funded health research into commercially-viable opportunities for Canada's private sector. This collaboration will help both organizations to achieve this goal. In doing so, CDRD and NRC will support the development of Canada's life sciences industry, and ensure that funding governments maximize the economic and societal return on their research investments.

About CDRD

The Centre for Drug Research and Development (CDRD), a national Centre of Excellence for Commercialization and Research (CECR), is a not-for-profit public-private organization that provides drug development expertise and infrastructure to enable researchers from leading academic and health research institutions to advance promising, early-stage drug candidates. To date, CDRD has supported some 95 research projects generated from its network of 20+ affiliated research institutions across Canada. These institutions represent billions invested in health-related research every year, and CDRD plays a pivotal role in translating that research into commercial products and economic returns including new jobs for British Columbia and Canada. For additional information, visit www.cdrd.ca.

Contact Information

  • The Centre for Drug Research and Development
    Barry Gee
    Director, Communications
    (604) 221-7750 x223
    bgee@cdrd.ca
    www.cdrd.ca